Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 Targeting the HuR oncogenic role with a new class of cytoplasmic dimerization inhibitorsCancer Research.  81:2220-2233. 2021
2019 Quality of Care for Veterans With In-Hospital Stroke.Federal practitioner : for the health care professionals of the VA, DoD, and PHS.  36:365-369. 2019
2019 Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cellsCancer Biology and Therapy.  20:979-988. 2019
2018 Characterization of the transient middle cerebral artery occlusion model of ischemic stroke in a HuR transgenic mouse line.Data in Brief.  16:1083-1090. 2018
2014 Smads as muscle biomarkers in amyotrophic lateral sclerosisAnnals of Clinical and Translational Neurology.  1:778-787. 2014
2013 Epidemiological features of amyotrophic lateral sclerosis in a large clinic-based African American population 2013
2008 Tristetraprolin down-regulates interleukin-8 and vascular endothelial growth factor in malignant glioma cellsCancer Research.  68:674-682. 2008
2005 Anti-Hu antibody neuropathy: A clinical, electrophysiological, and pathological study 2005
2003 Tumor necrosis factor α induces angiogenic factor up-regulation in malignant glioma cells: A role for RNA stabilization and HuRCancer Research.  63:4181-4187. 2003
2002 Human cytomegalovirus infection and expression in human malignant gliomaCancer Research.  62:3347-3350. 2002
2001 HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3′ untranslated regions of cytokine and angiogenic factor mRNAsCancer Research.  61:2154-2161. 2001
1998 Charcot-Marie-Tooth phenotype produced by a duplicated PMP22 gene as part of a 17p trisomy-translocation to the X chromosome. 1998
1997 Neuron-specific hel-N1 and HuD as novel molecular markers of neuroblastoma: a correlation of HuD messenger RNA levels with favorable prognostic features.Clinical Cancer Research.  3:1859-1865. 1997
1996 Cloning the 5' flanking region of neuron-specific Hel-N1: evidence for positive regulatory elements governing cell-specific transcription.Brain Research.  723:141-147. 1996
1996 Expression of Hel-N1 and Hel-N2 in small-cell lung carcinoma.Annals of Neurology.  39:679-681. 1996
1994 Autoantibodies against the Hel‐N1 RNA‐binding protein among patients with lung carcinoma: An association with type I anti–neuronal nuclear antibodiesAnnals of Neurology.  36:200-205. 1994
1987 Microinjection of a benzodiazepine into substantia nigra elevates kindled seizure threshold.Brain Research.  423:261-268. 1987

Education And Training

  • University Hospitals Case Medical Center, Internship
  • Duke University Medical Center, Residency
  • University Hospitals Case Medical Center, Residency
  • Cleveland Clinic Foundation, Postdoctoral Fellowship
  • Duke University Medical Center, Postdoctoral Fellowship
  • UAB Hospital, Postdoctoral Fellowship
  • Doctor of Medicine, Duke University 1985
  • Full Name

  • Peter King